A phase I dose‐ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities

Saved in:
Bibliographic Details
Published inBritish journal of haematology Vol. 178; no. 5; pp. 820 - 823
Main Authors Danilov, Alexey V., Lewis, Lionel D., Lansigan, Frederick, Roudaia, Liya, Findley, Darcie L., Jones, Susan Y., Highhouse, Brian, Beaulieu, Bernard B., Brown, Jennifer R.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.09.2017
Subjects
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
bendamustine
Bendamustine Hydrochloride - administration & dosage
chronic lymphocytic leukaemia
Chronic lymphocytic leukemia
comorbidities
Comorbidity
Hematology
Humans
Immunotherapy
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell - mortality
Lymphatic leukemia
Monoclonal antibodies
Rituximab
Rituximab - administration & dosage
Targeted cancer therapy
Treatment Outcome
comorbidities
chronic lymphocytic leukaemia
bendamustine
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ObjectType-Feature-3
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.14171